États-Unis · Plateformes & données · MarketBeat

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citigroup Analyst Says

Publié par MarketBeat · États-Unis il y a 37 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Citigroup increased their price objective on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the stock a "buy" rating in a research note on Wednesday.

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citigroup Analyst Says

Résumé détaillé

À lire aussi

Solid but narrow footing: UBS sees 3.5% global growth driven by AI capex

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Northrop Grumman at Baird conference sees durable demand, growth

Need money for a down payment? More employers are offering to help.

Crypto-Style Perpetual Futures Will Soon Be Available For Individual Stocks. Here's What Investors Need to Know.

Cathie Wood issues bullish Bitcoin prediction against gold

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citigroup Analyst Says

Résumé détaillé

Partager

À lire aussi

Solid but narrow footing: UBS sees 3.5% global growth driven by AI capex

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Northrop Grumman at Baird conference sees durable demand, growth

Need money for a down payment? More employers are offering to help.

Crypto-Style Perpetual Futures Will Soon Be Available For Individual Stocks. Here's What Investors Need to Know.

Cathie Wood issues bullish Bitcoin prediction against gold